| Title: |
5058 Bevacizumab (Bev) combined with either capecitabine (X) or weekly paclitaxel (Pac) as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer (LR/MBC): the CECOG phase III TURANDOT trial |
| Authors: |
Lang, I.; Inbar, M.; Steger, G.; Greil, R.; Zvirbule, Z.; Beslija, S.; Kahán, Z.; Taskova, V.; Kaufmann, B.; Zielinski, C.C. |
| Source: |
European Journal of Cancer Supplements ; volume 7, issue 2, page 277-278 ; ISSN 1359-6349 |
| Publisher Information: |
Elsevier BV |
| Publication Year: |
2009 |
| Collection: |
ScienceDirect (Elsevier - Open Access Articles via Crossref) |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| DOI: |
10.1016/s1359-6349(09)70950-4 |
| Availability: |
http://dx.doi.org/10.1016/s1359-6349(09)70950-4; https://api.elsevier.com/content/article/PII:S1359634909709504?httpAccept=text/xml; https://api.elsevier.com/content/article/PII:S1359634909709504?httpAccept=text/plain |
| Rights: |
https://www.elsevier.com/tdm/userlicense/1.0/ |
| Accession Number: |
edsbas.CAD4B17C |
| Database: |
BASE |